Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 30 September 2020
Name of applicant: |
SHIELD THERAPEUTICS PLC
|
|||
Name of scheme: |
S hield Therapeutics Retention Share Plan |
|||
Period of return: |
From: |
06 March 2020 |
To: |
30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: |
54,219 |
|||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
54,219 |
|||
Name of applicant: |
SHIELD THERAPEUTICS PLC
|
|||
Name of scheme: |
Shield Therapeutics plc 2016 Company Share Option Plan |
|||
Period of return: |
From: |
06 March 2020 |
To: |
30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: |
388,079 |
|||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
388,079 |
|||
Name of applicant: |
SHIELD THERAPEUTICS PLC
|
|||
Name of scheme: |
The Shield Therapeutics plc 2016 Long Term Incentive Plan |
|||
Period of return: |
From: |
06 March 2020 |
To: |
30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: |
171,883 |
|||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
171,883 |
|||
Name of applicant: |
SHIELD THERAPEUTICS PLC |
|||
Name of scheme: |
Shield Therapeutics Retention and Performance Share Plan |
|||
Period of return: |
From: |
06 March 2020 |
To: |
30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: |
1,885,819 |
|||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
1,885,819 |
|||
Name of contact: |
Lucy Huntington-Bailey |
Telephone number of contact: |
+44 (0) 191 511 8500 |
For further information please contact:
Shield Therapeutics plc |
|
Tim Watts, Chief Executive Officer |
+44 (0)20 7186 8500 |
Lucy Huntington-Bailey, General Counsel and Company Secretary |
+44 (0) 19 1511 8500 |
|
|
Nominated Advisor and Broker |
|
Peel Hunt LLP |
|
James Steel/Dr Christopher Golden |
+44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne |
+44 (0)7980 541 893 / +44 (0)7584 391 303 |
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx